Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

Abstract Background The effect of combined insulin and dipeptidyl peptidase-4 inhibitor (DPP4i) therapy on major adverse cardiovascular events (MACEs) in patients with diabetic foot is unclear. Methods We conducted this nationwide cohort study using longitudinal claims data obtained from the Taiwan...

Full description

Bibliographic Details
Main Authors: Yi-Hsuan Lin, Yu-Yao Huang, Yi-Ling Wu, Cheng-Wei Lin, Pei-Chun Chen, Chee Jen Chang, Sheng-Hwu Hsieh, Jui-Hung Sun, Szu-Tah Chen, Chia-Hung Lin
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Diabetic foot
Dipeptidyl peptidase-4 inhibitor-based therapy
Insulin therapy
Cardiovascular complications
Online Access:http://link.springer.com/article/10.1186/s13098-018-0378-6

Internet

http://link.springer.com/article/10.1186/s13098-018-0378-6

Similar Items